Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 1317784
Species: Homo sapiens
RGD Object: Gene
Symbol: CYP2C9
Name: cytochrome P450 family 2 subfamily C member 9
Acc ID: CHEBI:77780
Term: sulfaphenazole
Definition: A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.
Chemical ID: MESH:D013426
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
CYP2C9decreases activityEXP 6480464CTDSulfaphenazole results in decreased activity of CYP2C9 proteinPMID:12464242 PMID:12467917 PMID:12814958 PMID:15155557 PMID:15306208 PMID:15333513 PMID:15843491 PMID:15855725 PMID:15860655 PMID:17994679 PMID:19328226 PMID:21336516 PMID:21915887 PMID:22447115 PMID:23850985 PMID:26599973 PMID:28119166 PMID:33253783 PMID:33438235
CYP2C9decreases expressionEXP 6480464CTDSulfaphenazole results in decreased expression of CYP2C9 mRNAPMID:24519941
CYP2C9increases metabolic processingEXP 6480464CTDCYP2C9 protein results in increased metabolism of SulfaphenazolePMID:17702393 PMID:19309152
CYP2C9multiple interactionsEXP 6480464CTD[Butyric Acid co-treated with Sulfaphenazole] inhibits the reaction [Oxalic Acid results in increased expression of CYP2C9 mRNA]; [Sulfaphenazole results in decreased activity of CYP2C9 protein] which results in decreased metabolism of Diclofenac; Sulfaphenazole inhibits the reaction [[CYP2C9 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 4'-hydroxydiclofenac]; Sulfaphenazole inhibits the reaction [[CYP2C9 protein results in increased metabolism of dibenzylfluorescein] which results in increased chemical synthesis of Fluorescein]; Sulfaphenazole inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 11,12-epoxy-5,8,14-eicosatrienoic acid]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 4'-hydroxytolbutamide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased hydrolysis of Tolbutamide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of Arachidonic Acid]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of auriculasin]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of Diclofenac]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased oxidation of 2-oxo-clopidogrel]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased susceptibility to Cyclophosphamide]; Sulfaphenazole inhibits the reaction [methysticin results in decreased activity of CYP2C9 protein]; Sulfaphenazole inhibits the reaction [Oxalic Acid results in increased expression of CYP2C9 mRNA]PMID:10991840 PMID:11377097 PMID:12569440 PMID:12675279 PMID:16081671 PMID:19697924 PMID:19812348 PMID:21915887 PMID:22447115 PMID:23850985 PMID:24246759 PMID:26599973 PMID:28119166 PMID:31515991 PMID:35583123 PMID:37414240
Go Back to source page   Continue to Ontology report